Gastrointestinal Imaging

What Is the Best Imaging for a New Liver Lesion in a Patient with Known Cancer?

·
What Is the Best Imaging for a New Liver Lesion in a Patient with Known Cancer?

An oncologist calls you about a 68-year-old patient with a history of breast cancer, now five years in remission. A screening abdominal ultrasound, ordered for unrelated reasons, revealed a new, indeterminate 2.2 cm hypoechoic lesion in the right hepatic lobe. The patient is asymptomatic, and their liver function tests are normal. The immediate question is stark: Is this a benign incidental finding or the first sign of metastatic disease? This decision point is critical, as it dictates the patient’s entire subsequent oncologic pathway. This article provides a step-by-step clinical workflow for this exact scenario, guided by the American College of Radiology (ACR) Appropriateness Criteria. For this presentation, the ACR rates an MRI abdomen without and with IV contrast as Usually appropriate.

Who Fits This Clinical Scenario?

This guidance is specifically for patients who meet all of the following criteria:

  • An indeterminate liver lesion greater than 1 cm was found on an initial ultrasound. “Indeterminate” means the sonographic features are not characteristic of a simple cyst or classic hemangioma.
  • The patient has a known history of an extrahepatic malignancy (e.g., colon, breast, lung, melanoma). This history significantly raises the pre-test probability of the lesion being a metastasis.

This workflow does not apply to several similar-but-distinct clinical situations, which have their own diagnostic pathways:

  • No History of Malignancy: If the same lesion were found in a patient with no cancer history and a normal liver, the differential diagnosis and imaging urgency would be different.
  • Known Chronic Liver Disease: In a patient with cirrhosis or chronic hepatitis, the primary concern for a new liver lesion is hepatocellular carcinoma (HCC), which is evaluated using the LI-RADS system, a different diagnostic algorithm.
  • Lesion is Less Than 1 cm: For sub-centimeter lesions, the approach is often initial surveillance rather than immediate characterization, as they are frequently benign and challenging to fully characterize with imaging. This is a separate ACR variant.

Correctly identifying your patient’s scenario is the first step to avoiding unnecessary testing and reaching the right diagnosis efficiently.

What Diagnoses Are You Working Up in This Scenario?

When an indeterminate liver lesion appears in a patient with a known extrahepatic malignancy, the differential diagnosis is focused and prioritized. The goal of imaging is to distinguish between a consequential new metastasis and a benign “leave-me-alone” lesion.

Liver Metastasis
This is the primary and most urgent consideration. The liver’s dual blood supply and filtration role make it a common site for hematogenous spread from many cancers, particularly those of the gastrointestinal tract, breast, lung, and pancreas. The appearance of a new liver lesion in this context must be considered a metastasis until proven otherwise, as its confirmation would typically signify stage IV disease and necessitate a major change in treatment, often to systemic therapy.

Benign Liver Lesion
Benign lesions like hemangiomas, focal nodular hyperplasia (FNH), and hepatic adenomas are extremely common in the general population. A patient’s history of cancer does not preclude them from developing these. In fact, a significant portion of new liver lesions found in cancer patients turn out to be benign. Mischaracterizing a benign lesion as a metastasis can lead to profound patient anxiety, unnecessary invasive procedures like biopsy, and incorrect, potentially toxic, cancer treatments.

Primary Liver Malignancy
While less common in a liver without underlying cirrhosis, a primary liver cancer like hepatocellular carcinoma (HCC) or cholangiocarcinoma remains a possibility. This is a less frequent consideration than metastasis in this specific scenario but must be kept on the differential, as its treatment and prognosis differ significantly.

Why Is MRI Abdomen Without and With IV Contrast the Recommended Study?

The ACR designates MRI abdomen without and with IV contrast as a Usually appropriate study for this scenario, making it the top-line recommendation. Its superior soft-tissue contrast resolution allows for detailed characterization of liver parenchyma and lesions, often providing a definitive diagnosis without the need for more invasive testing.

The strength of a multiphase liver MRI lies in its ability to assess lesion enhancement patterns over time after the administration of a gadolinium-based contrast agent. Different lesions have characteristic vascular signatures. For example, a classic hemangioma shows peripheral nodular enhancement that fills in centripetally over time. Hypervascular metastases (from renal cell carcinoma, neuroendocrine tumors, melanoma) enhance avidly in the arterial phase. Hypovascular metastases (from colon or breast cancer) are often best seen as hypoenhancing defects in the portal venous phase.

Furthermore, specific MRI sequences add diagnostic confidence. Diffusion-weighted imaging (DWI) can help differentiate malignant lesions, which typically show restricted diffusion, from benign cysts and most benign solid lesions. The use of hepatobiliary agents (e.g., gadoxetate disodium) adds another layer of information, as functioning hepatocytes take up the agent, making lesions without hepatocytes (like most metastases) stand out on delayed imaging.

Comparison to Other Modalities

  • CT abdomen with IV contrast multiphase: This study is also rated Usually appropriate. It is faster and more widely available than MRI. However, it exposes the patient to ionizing radiation (ACR Relative Radiation Level ☢☢☢☢, 10-30 mSv) and generally has lower contrast resolution for subtle liver lesions compared to MRI. MRI is often superior for differentiating small metastases from benign lesions.
  • Image-guided biopsy liver: This is rated May be appropriate. Biopsy is the gold standard for a tissue diagnosis but is invasive and carries risks of bleeding, infection, and, rarely, tumor seeding along the needle tract. It is typically reserved for cases where high-quality, non-invasive imaging remains indeterminate and a definitive diagnosis is required to guide a critical management decision.
  • FDG-PET/CT: Also rated May be appropriate, this is a powerful tool for staging and assessing metabolic activity. However, it is not the ideal first-line study for characterizing an unknown liver lesion. Some slow-growing or small metastases may not be FDG-avid, leading to false negatives, while inflammatory processes can be FDG-avid, causing false positives. It is often used for whole-body staging after a lesion has been identified as suspicious for metastasis.

What’s Next After MRI? Downstream Workflow

The results of the contrast-enhanced MRI will guide the subsequent clinical pathway. The goal is to move from an indeterminate finding to a confident diagnosis that informs the patient’s oncologic care plan.

If the MRI shows a definitive metastasis:
The next step is a consultation with the patient’s oncologist. This finding typically prompts a full disease restaging, which may involve a PET/CT scan to look for other sites of metastatic disease. The confirmation of liver metastases often leads to a change in therapy, usually involving the initiation or modification of systemic treatment like chemotherapy, immunotherapy, or targeted therapy.

If the MRI shows a classic benign lesion (e.g., hemangioma, FNH, simple cyst):
This is a reassuring result. The lesion is considered an incidental finding unrelated to the patient’s cancer history. No further workup or follow-up for this specific liver lesion is necessary. The patient can continue their standard oncologic surveillance as previously planned.

If the MRI remains indeterminate or equivocal:
While MRI is highly accurate, some lesions may not display classic features. In this situation, the decision-making becomes more complex and patient-specific. The options, which should be discussed in a multidisciplinary setting (e.g., tumor board), include:

  • Short-term follow-up MRI: If the suspicion for malignancy is low, a follow-up scan in 3-6 months can assess for stability, which would favor a benign etiology.
  • Image-guided biopsy: If the clinical suspicion is high and a definitive diagnosis will immediately alter therapy (e.g., starting systemic chemotherapy), proceeding to a biopsy is the most direct path to a tissue diagnosis.
  • Alternative imaging: A PET/CT or contrast-enhanced ultrasound (CEUS) may provide complementary information to help characterize the lesion.

Pitfalls to Avoid (and When to Get Help)

Navigating this clinical scenario requires careful attention to detail to avoid common missteps that can delay diagnosis or lead to unnecessary procedures.

  • Pitfall 1: Accepting “benign-appearing” on ultrasound. In a patient with a known malignancy, the threshold for further investigation must be low. Features that might suggest a benign lesion in a healthy patient are not sufficient to rule out metastasis in this high-risk context.
  • Pitfall 2: Ordering the wrong MRI protocol. Simply ordering an “MRI Abdomen” may not be sufficient. You must specify “without and with IV contrast” and ensure your institution uses a dedicated multiphase liver protocol for optimal lesion characterization.
  • Pitfall 3: Prematurely ordering a biopsy. Jumping to an invasive biopsy before obtaining high-quality cross-sectional imaging is a common error. A definitive MRI can often obviate the need for a biopsy and its associated risks.
  • Pitfall 4: Ignoring MRI contraindications. Always screen for absolute contraindications (e.g., certain pacemakers, cochlear implants) and relative ones (e.g., severe renal impairment, which increases risk with gadolinium-based contrast agents).

If the imaging results remain equivocal after an MRI and the management decision is high-stakes, this is the time to escalate. Presenting the case at a multidisciplinary tumor board involving radiologists, oncologists, surgeons, and pathologists is the best way to reach a consensus on the next best step.

Related ACR Topics and Tools

This article focuses on one specific clinical variant. For a comprehensive overview of all scenarios related to the initial characterization of a liver lesion, please consult the parent topic article. For additional resources to help with imaging decisions, see the tools below.

Frequently Asked Questions

Why not just order a PET/CT scan first for a patient with a cancer history?

While PET/CT is excellent for whole-body staging and assessing metabolic activity, it is not the primary tool for initial lesion characterization. MRI provides superior anatomical detail and tissue-specific information (like vascular enhancement patterns) that are crucial for distinguishing a metastasis from a benign lesion like a hemangioma. A PET/CT may be the next step after MRI confirms a metastasis, but MRI is the better first choice for diagnosis.

What if my patient has a contraindication to MRI contrast, like severe kidney disease?

If a gadolinium-based contrast agent is contraindicated due to severe renal dysfunction (low eGFR), the next best options should be considered. A non-contrast MRI may still provide useful information, particularly with diffusion-weighted sequences. Alternatively, a multiphase contrast-enhanced CT is also rated ‘Usually appropriate’ and would be a strong choice. Contrast-enhanced ultrasound (CEUS) is another excellent, radiation-free option rated ‘May be appropriate’ if available at your institution, as the ultrasound contrast agents are not nephrotoxic.

Does the type of primary extrahepatic cancer change this recommendation?

No, the initial recommendation for a contrast-enhanced MRI remains the same regardless of the primary cancer type. However, the primary cancer can influence the interpretation of the MRI. For example, metastases from neuroendocrine tumors or renal cell carcinoma are typically hypervascular, while those from colon cancer are often hypovascular. This knowledge helps the radiologist interpret the enhancement patterns, but the choice of MRI as the best characterization tool is consistent.

What if the indeterminate lesion found on ultrasound was smaller than 1 cm?

That is a different clinical scenario with a separate ACR recommendation. For indeterminate lesions less than 1 cm, the ACR often suggests a period of surveillance with follow-up imaging (e.g., ultrasound or MRI in 3-6 months) rather than an immediate, full characterization workup. This is because sub-centimeter lesions are very often benign and are difficult to definitively characterize with any modality.

Is contrast-enhanced ultrasound (CEUS) a good alternative to MRI or CT?

Yes, CEUS is rated ‘May be appropriate’ and can be an excellent problem-solving tool. It uses microbubble contrast agents that are not harmful to the kidneys and provides real-time dynamic enhancement information, which can be very effective for characterizing liver lesions. Its main limitations are that it is not as widely available as CT or MRI, can be operator-dependent, and may have difficulty evaluating very deep lesions or the entire liver in patients with a large body habitus.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 26, 2026